REG - Royal Bk Scot.Grp. - Publication of Suppl.Prospcts

NatwestAnnouncement

29/04/2019 11:10

RNS Number : 3973X
Royal Bank of Scotland Group PLC
29 April 2019
 


Publication of Supplementary Prospectus
The following supplementary prospectus has been approved by the Financial Conduct Authority and is available for viewing:
3rd Supplementary Prospectus to The Royal Bank of Scotland Group plc £40,000,000,000 Euro Medium Term Note Programme dated 26 April 2019.
To view the full document, please paste the following URL into the address bar of your browser:
http://www.rns-pdf.londonstockexchange.com/rns/3973X_1-2019-4-29.pdf
A copy of the above 3rd Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.
For further information, please contact:
 
Scott Forrest
Head of RBS Debt Capital Markets & Capital Strategy
Tel: +44 (0) 131 626 1329
 
 
DISCLAIMER - INTENDED ADDRESSEES
Please note that the information contained in the 3rd Supplementary Prospectus (and the Prospectus to which it relates) may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the Prospectus and the 3rd Supplementary Prospectus is not addressed. Prior to relying on the information contained in the Prospectus and the 3rd Supplementary Prospectus you must ascertain from the Prospectus whether or not you are part of the intended addressees of the information contained therein.
Your right to access this service is conditional upon complying with the above requirement.
 
Legal Entity Identifier




 


 




The Royal Bank of Scotland Group plc


2138005O9XJIJN4JPN90




 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PSPDMGZDLLNGLZG